AI guides

Bessemer and Bain survey healthcare AI returns: administration outpaces clinical uses

By 智药局0 viewsSource: 智药局
Bessemer and Bain healthcare AI return-on-investment survey

A survey of 226 executives reports average returns of about 3.5x, with higher returns in revenue-cycle management and lower returns in clinical development. Sample definitions, evaluation windows and long-term clinical outcomes must be distinguished.

Editorial correction (November 16, 2026): ROI figures reflect the survey sample and report definitions, not returns or clinical efficacy for every deployment. Annual healthcare spending is not the same as revenue available to AI.

How much has AI investment returned for providers, insurers and pharmaceutical companies?

Leading US venture firm Bessemer (Bessemer Venture Partners) and consultancy Bain (Bain & Company) recently released The 2026 Healthcare AI ROI Scorecard to address that question.

The report surveys 226 healthcare executives, comparing providers, payers and pharmaceutical companies to track 2026 returns on AI investment.

It finds returns arriving sooner and higher than expected: realized after 12 months rather than the anticipated roughly 24, averaging 3.5x, with about 40% of use cases exceeding expectations.

Article illustration

Differences are substantial, however: mature administrative processes show the highest returns, clinical settings the lowest.

Three scorecards: back-office work leads, clinical work trails

Bessemer says all surveyed business areas meet or approach companies' required 3x threshold. The decision is shifting from whether to invest to which areas deserve priority.

Article illustration

Providers' revenue-cycle management (RCM) leads with 4x ROI, while clinical applications return 2.9x, below the 3x threshold.

Clinical value is harder to calculate. The report says benefits mainly come from improved decisions and care, with little contribution to labor savings or revenue growth.

However, when it comes to decision-making, although AI has already been embedded in workflows, it has not earned trust. Only 46% of healthcare workers would trust AI-assisted clinical decision-making. And 77% of medical staff say that more than half of the recommendations AI provides are rejected outright.

The RCM/clinical return gap also appears in adoption.

About two-thirds of RCM staff use semiautonomous or autonomous agents, versus only 4% in clinical care.

Article illustration

Responsibility partly explains this. Fifty-eight percent of providers believe attending physicians should bear primary responsibility for AI-assisted diagnosis and treatment, and liability concerns hinder wider adoption.

Reimbursement is another obstacle. About 48% of payers oppose covering fully autonomous AI care, versus only 5% opposing physician-reviewed AI-assisted care.

Therefore, expanding the use of clinical AI requires answering several questions at the same time: Are AI recommendations reliable? Who takes responsibility when something goes wrong? Who bears the cost of the service?

Where the next AI expansion may occur

Pharmaceutical returns are developing most slowly among the three sectors, with clearer benefits concentrated upstream in the pipeline.

Preclinical R&D returns 3.4x, tied for second with insurance claims and also pharma's most widely adopted AI area.

More specifically, preclinical molecule identification and structural design have generated returns near 5x.

Article illustration

Y-axis: return on investment

X-axis: industry adoption

Clinical development averages only 2.3x, last in the ranking and below the expected 3x threshold.

A major reason is drug development's duration, far beyond a one-year evaluation window, making attribution difficult.

AI can show efficiency gains relatively early in upstream stages such as molecular design. But once drug candidates enter clinical trials, their safety and efficacy still need to be validated, and the ultimate returns often cannot be confirmed until years later.

Lower current clinical-development returns do not mean lower long-term value. Preclinical work accounts for only about one-quarter of pharma R&D spending, with more investment downstream.

That spending share does not guarantee AI value will shift to clinical development. Candidates must still demonstrate safety, efficacy and economic viability; whether and when returns materialize remains uncertain.

As returns become clearer, another question emerges: who supplies these capabilities?

Over the past year, enthusiasm for in-house AI has declined. Sixty-one percent of organizations say half or fewer of their internally built tools remain maintained and used. The in-house-development share fell 16 percentage points, while healthcare-specific AI vendors gained 12 points.

The report expects buyers to seek solutions from AI startups, scaled companies and AI labs over the next decade.

Among them, AI labs merit particular attention. Though adoption rose only two percentage points, pharma views them as its future preferred partner type, with the highest favorability among buyer groups.

Annual healthcare spending and potential AI opportunities

The report discusses transformation across administration, clinical services and medicines. The approximately $4.5 trillion cited totals spending in those areas; it is not directly the revenue AI services could obtain.

$1 trillion: administrative disputes

US healthcare administration costs about $1 trillion annually, roughly $260 billion of it waste. Much comes from repeated provider–payer negotiations over authorization, denials and appeals. AI on both sides may improve each organization's efficiency while still performing essentially the same work twice.

The true trillion-dollar-scale value would be eliminating such processes.

This requires intermediary AI vendors capable of serving both the supply and demand sides simultaneously. It also requires redesigning the accompanying incentive mechanisms, and the latter is not something AI can solve on its own.

$3 trillion: clinical services

This is the largest opportunity and one most likely to emerge first.

US medical-service spending is about $3 trillion annually, growing roughly 5%, while staffing shortages widen. The Association of American Medical Colleges projects a shortage of up to 86,000 physicians by 2036.

Greater shortages increase AI's appeal, but doctors' and patients' trust requires clearer responsibility first.

$500 billion: drug development and distribution

US drug spending is about $500 billion annually, with pharma R&D around $150 billion. AI currently adds value upstream, but candidates still face safety, efficacy and accessibility tests in clinical development.

Longer downstream realization times are the largest bottleneck in this opportunity.

Each area faces a different next-stage barrier: administration must reduce repetitive disputes, clinical care needs trust and accountability, and drug development needs shorter validation cycles.

Model upgrades alone cannot solve every deployment problem.

Closing thoughts

At its conclusion, the report notes that outside healthcare, AI agent teams have already established a standard infrastructure stack, including evaluation, performance monitoring, safety guardrails and agent orchestration.

Average 3.5x returns give buyers reason to keep investing. The next question is whether AI can move beyond validated billing and claims use cases to deliver greater value in care and drug development.

This article comes from the Zhiyaoju WeChat account. Author: Zhiyaoju.

After reading

Join the AINRK community

Read how to join the community and connect with people working in AI.

Community information (opens in a new tab)